3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Melanoma
2
Carcinoma, Renal Cell
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Interventions
pembrolizumab
35
Nivolumab
14
Docetaxel
11
atezolizumab
10
Paclitaxel
9
Carboplatin
7
Gemcitabine
6
Cisplatin
6
Trastuzumab
5
Magnetic Resonance Spectroscopy
5
Ipilimumab
5
Fluorodeoxyglucose F18
5
Cyclophosphamide
5
Bevacizumab
5
fludarabine
4
avelumab
4
Specimen Handling
4
Psychiatric Rehabilitation
4
Oxaliplatin
4
Leucovorin
4
Fluorouracil
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
cemiplimab
3
Taxes
3
Polymerase Chain Reaction
3
Pemetrexed
3
Irinotecan
3
Gene Expression Profiling
3
Early Intervention, Educational
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
Interleukin-15
×
Genitourinary
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled